Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Importance: Finding a reliable diagnostic biomarker for the disorders collectively known as synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an urgent unmet need. Immunohistochemical detection of cutaneous phosphorylated α-synuclein may be a sensitive and specific clinical test for the diagnosis of synucleinopathies. Objective: To evaluate the positivity rate of cutaneous α-synuclein deposition in patients with PD, DLB, MSA, and PAF. Design, Setting, and Participants: This blinded, 30-site, cross-sectional study of academic and community-based neurology practices conducted from February 2021 through March 2023 included patients aged 40 to 99 years with a clinical diagnosis of PD, DLB, MSA, or PAF based on clinical consensus criteria and confirmed by an expert review panel and control participants aged 40 to 99 years with no history of examination findings or symptoms suggestive of a synucleinopathy or neurodegenerative disease. All participants completed detailed neurologic examinations and disease-specific questionnaires and underwent skin biopsy for detection of phosphorylated α-synuclein. An expert review panel blinded to pathologic data determined the final participant diagnosis. Exposure: Skin biopsy for detection of phosphorylated α-synuclein. Main Outcomes: Rates of detection of cutaneous α-synuclein in patients with PD, MSA, DLB, and PAF and controls without synucleinopathy. Results: Of 428 enrolled participants, 343 were included in the primary analysis (mean [SD] age, 69.5 [9.1] years; 175 [51.0%] male); 223 met the consensus criteria for a synucleinopathy and 120 met criteria as controls after expert panel review. The proportions of individuals with cutaneous phosphorylated α-synuclein detected by skin biopsy were 92.7% (89 of 96) with PD, 98.2% (54 of 55) with MSA, 96.0% (48 of 50) with DLB, and 100% (22 of 22) with PAF; 3.3% (4 of 120) of controls had cutaneous phosphorylated α-synuclein detected. Conclusions and Relevance: In this cross-sectional study, a high proportion of individuals meeting clinical consensus criteria for PD, DLB, MSA, and PAF had phosphorylated α-synuclein detected by skin biopsy. Further research is needed in unselected clinical populations to externally validate the findings and fully characterize the potential role of skin biopsy detection of phosphorylated α-synuclein in clinical care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationSecond consensus statement on the diagnosis of multiple system atrophy
Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Dürr, A., Fowler, C. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324625.00404.15 · Cited by 3,140
Self-citationThe Statistical Evaluation of Medical Tests for Classification and Prediction
Pepe, M. S. (2003) · doi:10.1093/oso/9780198509844.001.0001 · Cited by 2,198
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Hughes, A. J., Ben-Shlomo, Y., Daniel, S. E., & Lees, A. J. (1992) · Neurology · doi:10.1212/wnl.42.6.1142 · Cited by 1,313
Prevalence of Parkinson’s disease across North America
Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0058-0 · Cited by 968
Siderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719
Self-citationNeuropathology of Parkinson disease
Dickson, D. W. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.033 · Cited by 623
When DLB, PD, and PSP masquerade as MSA: An autopsy study of 134 patients
Koga, S., Aoki, N., Uitti, R. J., van Gerpen, J. A., Cheshire, W. P., Josephs, K. A., Wszolek, Z. K., Langston, J. W., & Dickson, D. W. (2015) · Neurology · doi:10.1212/wnl.0000000000001807 · Cited by 358
Incidence of Dementia With Lewy Bodies and Parkinson Disease Dementia
Savica, R., Grossardt, B. R., Bower, J. H., Boeve, B. F., Ahlskog, J. E., & Rocca, W. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.3579 · Cited by 320
Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Wang, Z., Becker, K., Donadio, V., Siedlak, S., Yuan, J., Rezaee, M., Incensi, A., Kuzkina, A., Orrú, C. D., Tatsuoka, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3311 · Cited by 253
The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale
Kaufmann, H., Malamut, R., Norcliffe-Kaufmann, L., Rosa, K., & Freeman, R. (2012) · Clinical Autonomic Research · doi:10.1007/s10286-011-0146-2 · Cited by 245
Self-citationNeuropathological evidence of body-first vs. brain-first Lewy body disease
Borghammer, P., Horsager, J., Andersen, K., Van Den Berge, N., Raunio, A., Murayama, S., Parkkinen, L., & Myllykangas, L. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105557 · Cited by 214
Incidence and Pathology of Synucleinopathies and Tauopathies Related to Parkinsonism
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.114 · Cited by 197
In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC
Donadio, V. A., Wang, Z., Incensi, A., Rizzo, G., Fileccia, E., Vacchiano, V., Capellari, S., Magnani, M., Scaglione, C. L. M., Maserati, M. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011935 · Cited by 167
Clinical implications of delayed orthostatic hypotension: A 10-year follow-up study
Gibbons, C. H., & Freeman, R. (2015) · Neurology · doi:10.1212/wnl.0000000000002030 · Cited by 148
Self-citationCutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Gibbons, C. H., Wang, N., Rajan, S., Kern, D. S., Palma, J., Kaufmann, H., & Freeman, R. L. (2023) · Neurology · doi:10.1212/wnl.0000000000206772 · Cited by 132
Self-citationIranzo, Á., Mammana, A., Lopetegi, A. M., Dellavalle, S., Mayà, G., Rossi, M., Serradell, M., Baiardi, S., Arqueros, A., Quadalti, C., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207147 · Cited by 120
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Boeve, B. F., Graff‐Radford, J., Rocca, W. A., & Mielke, M. M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0603 · Cited by 115
Different α-synuclein prion strains cause dementia with Lewy bodies and multiple system atrophy
Ayers, J. I., Lee, J., Monteiro, O., Woerman, A. L., Lazar, A., Condello, C., Paras, N. A., & Prusiner, S. B. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113489119 · Cited by 91
Goetz, C. G. (2009) · Revue Neurologique · doi:10.1016/j.neurol.2009.09.001 · Cited by 80
Wang, N., García, J. M., Freeman, R. L., & Gibbons, C. H. (2020) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155420960250 · Cited by 66
Self-citationPhosphorylated α-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy
Donadio, V., Incensi, A., Rizzo, G., Westermark, G. T., Devigili, G., Micco, R. D., Tessitore, A., Nyholm, D., Parisini, S., Nyman, D., et al. (2023) · Brain · doi:10.1093/brain/awac124 · Cited by 62
Gibbons, C. H., Freeman, R. L., Bellaire, B., Adler, C. H., Moore, D. H., & Levine, T. (2022) · Biomarkers in Medicine · doi:10.2217/bmm-2021-0646 · Cited by 40
Self-citation
Cited by
Tanner, C. M., & Ostrem, J. L. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401857 · Cited by 382
Metadata
- Authors
- Gibbons, C. H., Levine, T., Adler, C., Bellaire, B., Wang, N., Stohl, J., Agarwal, P., Aldridge, G. M., Barboi, A., Evidente, V. G. H., Galasko, D., Geschwind, M. D., Gonzalez-Duarte, A., Gil, R., Gudesblatt, M., Isaacson, S. H., Kaufmann, H., Khemani, P., Kumar, R., Lamotte, G., Liu, A. J., McFarland, N. R., Miglis, M., Reynolds, A., Sahagian, G. A., Saint-Hillaire, M.-H., Schwartzbard, J. B., Singer, W., Soileau, M. J., Vernino, S., Yerstein, O., & Freeman, R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-04-16
- Volume
- 331
- Issue
- 15
- Pages
- 1298
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4392986196
- Cited by
- 197
- References
- 25
- FWCI
- 45.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.